Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: A correlation with the expression of peroxisome proliferator-activated receptor-gamma

Thyroid

Volumn 18, Issue 7, 2008, Pages 697-704

  Tepmongkol, Supatporn ^a   Keelawat, Somboon ^a   Honsawek, Sittisak ^a   Ruangvejvorachai, Preecha ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; LEVOTHYROXINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RADIOACTIVE IODINE; ROSIGLITAZONE; THYROGLOBULIN;

ADULT; AGED; ARTICLE; BIOPSY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG UPTAKE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CARCINOMA, PAPILLARY; CARCINOMA, PAPILLARY, FOLLICULAR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IODINE; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PPAR GAMMA; THIAZOLIDINEDIONES; THYROGLOBULIN; THYROID NEOPLASMS; WHOLE BODY IMAGING;

EID: 47549109967     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2008.0056     Document Type: Article

References (28)

1. Soh EY, Clark OH 1996 Surgical considerations and approach to the thyroid cancer. Endocrinol Metab Clin North Am 25:115-139.
2. Diane CS, Gerald SJ 1995 Radioiodine therapy for thyroid cancer. Endocrinol Metab Clin North Am 24:803-812.
3. Matias-Guiu X, Cuatrecasas M, Musulen E, Prat J 1994 p53 expression in anaplastic carcinomas arising from thyroid papillary carcinomas. J Clin Pathol 47:337-339.
4. Ito Y, Yoshida H, Nakano K, Takamura Y, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Matsuura N, Kuma K, Miyauchi A 2003 Bag-1 expression in thyroid neoplasm: its correlation with Bcl-2 expression and carcinoma dedifferentiation. Anticancer Res 23:569-576.
5. Ito Y, Yoshida H, Nakano K, Takamura Y, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Matsuura N, Kuma K, Miyauchi A 2003 Syndecan-1 expression in thyroid carcinoma: stromal expression followed by epithelial expression is significantly correlated with dedifferentiation. Histopathology 43:157-164.
6. Ito Y, Yoshida H, Uruno T, Nakano K, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Matsuura N, Kakudo K, Kuma K, Miyauchi A 2003 Survivin expression is significantly linked to the dedifferentiation of thyroid carcinoma. Oncol Rep 10:1337-1340.
7. Santos L, Loo C, Chandraratnam E, Gune S 2004 Anaplastic carcinoma dedifferentiation of solid variant of papillary thyroid carcinoma. Pathology 36:196-211.
8. Furuya F, Shimura H, Suzuki H, Taki K, Ohta K, Haraguchi K, Onaya T, Endo T, Kobayashi T 2004 Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin. Endocrinology 145:2865-2875.
9. Coelho SM, Corbo R, Buescu A, Carvalho DP, Vaisman M 2004 Retinoic acid in patients with radioiodine nonresponsive thyroid carcinoma. J Endocrinol Invest 27:334-339.
10. Elisei R, Vivaldi A, Agate L, Ciampi R, Molinaro E, Piampiani P, Romei C, Faviana P, Basolo F, Miccoli P, Capodanno A, Collecchi P, Pacini F, Pinchera A 2005 All-trans retinoic acid treatment inhibits the growth of RAR{beta} mRNA expressing thyroid cancer cell lines but does not re-induce the expression of thyroid specific genes. J Clin Endocrinol Metab 90:2403-2411.
11. Klopper JP, Hays WR, Sharma V, Baumbusch MA, Hershman JM, Haugen BR 2004 Retinoid X receptor-gamma and peroxisome proliferator-activated receptor-gamma expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment. Mol Cancer Ther 3:1011-1020.
12. Auwerx J 1999 PPARγ, the ultimate thrifty gene. Diabetologia 42:1033-1049.
13. Vidal-Puig A, Jimenez-Liñan M, Lowell BB, Hamann A, Hu E, Spiegelman B, Flier JS, Moller DE 1996 Regulation of PPARg gene expression by nutrition and obesity in rodents. J Clin Invest 97:2553-2561.
14. Lefebvre AM, Laville M, Vega N, Riou JP, van Gaal L, Auwerx J, Vidal H 1998 Depot-specific differences in adipose tissue gene expression in lean and obese subjects. Diabetes 47:98-103.
15. Rieusset J, Andreelli F, Auboeuf D, Roques M, Vallier P, Riou JP, Auwerx J, Laville M, Vidal H 1999 Insulin acutely regulates the expression of the peroxisome proliferator-activated receptor γ in human adipocytes. Diabetes 48:699-705.
16. Ohta K, Endo T, Haraguchi K, Hershman JM, Onaya T 2001 Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 86:2170-2177.
17. Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, Eng C, Spiegelman BM, Kantoff PW 2000 Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA 97:10990-10995.
18. Smith MR, Manola J, Kaufman DS, George D, Oh WK, Mueller E, Slovin S, Spiegelman B, Small E, Kantoff PW 2004 Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer 101:1569-1574.
19. Nemec J, Rohling S, Zamrazil V, Pohunkova D 1979 Comparison of the distribution of diagnostic and thyroablative I-131 in the evaluation of differentiated thyroid cancers. J Nucl Med 20:92-97.
20. Sherman SI, Tielens ET, Sostre S, Wharam MD Jr., Ladenson PW 1994 Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab 78:629-634.
21. Chen WL, Guan SI, Huang WS 1993 Radioiodine I-131 therapy in the management of differentiated thyroid carcinoma: a review of 202 patients. J Formos Med Assoc 92:623-631.
22. Pace L, Klain M, Albanese C, Salvatore B, Storto G, Soricelli A, Salvatore M 2006 Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment. Eur J Nucl Med Mol Imaging 33:179-183.
23. Frohlich E, Fausto M, Wahl R 2005 Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture. Endocr Relat Cancer 12:291-303.
24. Trouttet-Masson S, Selmi-Ruby S, Bernier-Valentin F, Porra V, Berger-Dutrieux N, Decaussin M, Peix JL, Perrin A, Bournaud C, Orgiazzi J, Borson-Chazot F, Franc B, Rousset B 2004 Evidence for transcriptional and posttranscriptional alterations of the sodium/iodide symporter expression in hypofunctioning benign and malignant thyroid tumors. Am J Pathol 165:25-34.
25. Park JW, Zarnegar R, Kanauchi H, Wong MG, Hyun WC, Ginzinger DG, Lobo M, Cotter P, Duh QY, Clark OH 2005 Troglitazone, the peroxisome proliferator-activated receptor-γ agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. Thyroid 15:222-231.
26. Martelli ML, Iuliano R, Le Pera I, Sama' I, Monaco C, Cammarota S, Kroll T, Chiariotti L, Santoro M, Fusco A 2002 Inhibitory effects of peroxisome proliferator-activated receptor gamma on thyroid carcinoma cell growth. J Clin Endocrinol Metab 87:4728-4735.
27. Philips JC, Petite C, Willi JP, Buchegger F, Meier CA 2004 Effect of peroxisome proliferator-activated receptor [gamma] agonist, rosiglitazone, on dedifferentiated thyroid cancers. Nucl Med Commun 25:1183-1186.
28. Kebebew E, Peng M, Reiff E, Treseler P, Woeber KA, Clark OH, Greenspan FS, Lindsay S, Duh QY, Morita E 2006 A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer. Surgery 140:960-967.